Brokerages predict that GW Pharmaceuticals plc (NASDAQ:GWPH) will announce sales of $141.36 million for the current fiscal quarter, according to Zacks. Eight analysts have provided estimates for GW Pharmaceuticals' earnings, with the lowest sales estimate coming in at $135.10 million and the highest estimate coming in at $148.54 million. GW Pharmaceuticals reported sales of $109.08 million during the same quarter last year, which indicates a positive year-over-year growth rate of 29.6%. The company is expected to announce its next quarterly earnings report on Tuesday, February 23rd.
On average, analysts expect that GW Pharmaceuticals will report full-year sales of $521.84 million for the current fiscal year, with estimates ranging from $514.08 million to $533.81 million. For the next fiscal year, analysts anticipate that the business will report sales of $721.99 million, with estimates ranging from $662.70 million to $773.54 million. Zacks' sales calculations are an average based on a survey of sell-side research firms that follow GW Pharmaceuticals.
GW Pharmaceuticals (NASDAQ:GWPH) last issued its quarterly earnings data on Tuesday, November 3rd. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.63) by $0.27. GW Pharmaceuticals had a negative net margin of 11.05% and a negative return on equity of 7.46%. The business had revenue of $137.10 million during the quarter, compared to analysts' expectations of $97.66 million. During the same period last year, the company posted ($0.04) EPS. The company's revenue was up 50.7% on a year-over-year basis.
Several analysts have commented on the stock. Zacks Investment Research raised shares of GW Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Monday, October 26th. Cantor Fitzgerald lowered their target price on shares of GW Pharmaceuticals from $165.00 to $147.00 and set an "overweight" rating for the company in a research note on Tuesday. HC Wainwright reaffirmed a "buy" rating on shares of GW Pharmaceuticals in a research note on Wednesday, November 4th. Finally, ValuEngine cut shares of GW Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Thursday, September 3rd. One research analyst has rated the stock with a sell rating, five have issued a hold rating and ten have issued a buy rating to the stock. The company currently has an average rating of "Buy" and a consensus target price of $179.31.
In related news, insider Volker Knappertz sold 6,000 shares of GW Pharmaceuticals stock in a transaction on Wednesday, November 4th. The shares were sold at an average price of $9.17, for a total transaction of $55,020.00. Following the transaction, the insider now owns 41,940 shares in the company, valued at approximately $384,589.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Christopher J. Tovey sold 28,560 shares of GW Pharmaceuticals stock in a transaction on Tuesday, December 1st. The shares were sold at an average price of $11.76, for a total transaction of $335,865.60. The disclosure for this sale can be found here. Insiders have sold a total of 980,832 shares of company stock valued at $9,901,832 over the last three months. Corporate insiders own 3.10% of the company's stock.
Large investors have recently bought and sold shares of the stock. First Horizon Advisors Inc. lifted its holdings in shares of GW Pharmaceuticals by 317.5% during the 3rd quarter. First Horizon Advisors Inc. now owns 263 shares of the biopharmaceutical company's stock valued at $26,000 after acquiring an additional 200 shares in the last quarter. FNY Investment Advisers LLC acquired a new position in GW Pharmaceuticals in the 3rd quarter worth $33,000. Fifth Third Bancorp lifted its holdings in GW Pharmaceuticals by 18.9% in the 3rd quarter. Fifth Third Bancorp now owns 1,027 shares of the biopharmaceutical company's stock worth $100,000 after buying an additional 163 shares in the last quarter. SG Americas Securities LLC acquired a new position in GW Pharmaceuticals in the 3rd quarter worth $139,000. Finally, Rockefeller Capital Management L.P. lifted its holdings in GW Pharmaceuticals by 195.6% in the 2nd quarter. Rockefeller Capital Management L.P. now owns 1,676 shares of the biopharmaceutical company's stock worth $206,000 after buying an additional 1,109 shares in the last quarter. Institutional investors and hedge funds own 76.43% of the company's stock.
Shares of GWPH opened at $116.09 on Thursday. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.13 and a quick ratio of 4.31. The firm has a 50 day simple moving average of $123.75 and a 200-day simple moving average of $114.47. GW Pharmaceuticals has a 1-year low of $67.98 and a 1-year high of $144.00. The stock has a market cap of $3.60 billion, a price-to-earnings ratio of -67.49 and a beta of 2.25.
GW Pharmaceuticals Company Profile
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, Dravet syndrome, and Lennox-Gastaut syndrome, as well as in phase III clinical trials for the treatment of tuberous sclerosis complex.
See Also: What is the significance of a dead cat bounce?
Get a free copy of the Zacks research report on GW Pharmaceuticals (GWPH)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
7 Marijuana Stocks Worth Speculating On
To say it’s been a rough two years for the cannabis industry is an understatement. Due to a combination of issues (including some self-inflicted wounds), the cannabis boom predicted in 2018 has not materialized. But that could be about to change.
If Joe Biden wins the presidential election, it will likely be part of a “Blue Wave” that will bring Democratic party control of both houses of Congress. And even if President Trump successfully wins a second term, it is still possible that Republicans could lose their hold on the Senate.
The bottom line is there is a range of outcomes that are possible. Most of those outcomes are favorable to the legalization of marijuana. And even if cannabis is not made legal on the federal level, it seems likely that the remaining states holding out will take steps to legalization. That’s because, like gambling, cannabis may create an economic lift that cash-strapped states may find too difficult to turn down.
One thing is certain. If you wait until the right time, you’ll have missed out on some eye-popping initial gains. But to get that reward in the future, you’ll need to assume some risk now. In this special presentation, we’ve identified seven cannabis stocks that you can consider when evaluating your opportunity in the cannabis sector.
View the "7 Marijuana Stocks Worth Speculating On ".